Vincerx Pharma, Inc. VINC

Full chart Compare
Set alert

Price alert · VINC

All alert types
0.01 USD 0.00 (+0.00%)

At closeFeb 5, 2026, 4:00 PM EST

0.06 +0.05 +391.54%

After hours · Feb 5, 4:00 PM ET

0.0053 Day range 0.0053
0.005 52-week range 0.026
YTD
0.00%
1 year
-75.00%

Analyst view

Price target (mean) 6.00 +46053.8% upside
Target (low)
2.00
Target (mean)
6.00
Target (high)
10.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 2
  • 1 month ago 3

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

VINC analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter0.000.00 – 0.000.000.0%00.0%0
Current year0.000.00 – 0.000.000.0%00.0%0
Next year0.000.00 – 0.000.000.0%00.0%0

Upgrades and downgrades

The latest rating changes

VINC analyst upgrades and downgrades
DateFirmActionFromTo
Oct 8, 2024Leerink PartnersMaintainedOutperformOutperform
Apr 9, 2024Cantor FitzgeraldReiterated—Overweight
Apr 1, 2024Cantor FitzgeraldReiterated—Overweight
Sep 7, 2023Cantor FitzgeraldReiteratedOverweightOverweight
Nov 17, 2022Chardan CapitalMaintained—Buy
Aug 12, 2022SVB LeerinkMaintained—Outperform
Jun 8, 2022Cantor FitzgeraldMaintained—Overweight
Jun 7, 2022B. Riley SecuritiesMaintained—Buy
Jun 7, 2022Chardan CapitalMaintained—Buy
Jun 7, 2022SVB LeerinkMaintained—Outperform
May 13, 2022Chardan CapitalMaintained—Buy
May 13, 2022SVB LeerinkMaintained—Outperform
Mar 30, 2022SVB LeerinkMaintained—Outperform
Mar 30, 2022HC Wainwright & Co.Maintained—Buy
Jan 14, 2022HC Wainwright & Co.Initiated—Buy
Dec 23, 2021Cantor FitzgeraldInitiated—Overweight
Nov 1, 2021SVB LeerinkInitiated—Outperform
Sep 13, 2021Laidlaw & Co.Initiated—Buy
Aug 25, 2021B. Riley SecuritiesInitiated—Buy
Aug 13, 2021Chardan CapitalMaintained—Buy
Jan 6, 2021Chardan CapitalInitiated—Buy